COMPANION-002
CTX-009-002
Biliary Tract Cancer (BTC)
A Phase 2/3 study in adults with unresectable, advanced, metastatic or recurrent biliary tract cancer who have received one prior systemic chemotherapy regimen. This randomized study assesses the efficacy and safety of CTX-009 in combination with paclitaxel versus paclitaxel alone as a second-line therapy. The primary outcome is Overall Response Rate (ORR). Study enrollment is now closed.
Watch our presentation
COMPANION-003
CTX-009-003
Colorectal Cancer
A Phase 2 study in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens. This study assesses the efficacy and safety of CTX-009. The primary outcome is ORR (Overall Response Rate). Study enrollment is now closed.
CTX-471 + KEYTRUDA®
(pembrolizumab)
Solid Tumors
A Phase 1b arm for patients who have metastatic or locally advanced non-small cell lung cancer, melanoma, small cell lung cancer, mesothelioma, and head and neck cancer who have progressed after treatment with a checkpoint inhibitor. Patients enrolled in the study are treated with a combination of CTX-471 + KEYTRUDA® (pembrolizumab) with the goal of restoring response. Study enrollment is now closed.
CTX-8371
A Phase 1, multiple–ascending dose study to evaluate the safety, tolerability, immunogenicity, and pharmacokinetic profile of CTX-8371 monotherapy in patients with metastatic Malignant Melanoma, Head and Neck squamous cell carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, and Classical Hodgkin Lymphoma. Preliminary anti-tumor activity of CTX-8371 will also be assessed.
